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Abstract
Background: There is a large quality of care gap for patients with osteoporosis. As a fragility fracture is a strong
indicator of underlying osteoporosis, it offers an ideal opportunity to initiate investigation and treatment. However,
studies of post-fracture populations document screening and treatment rates below 20% in most settings. This is
despite the fact that bone mineral density (BMD) scans are effective at identifying patients at high risk of fracture,
and effective drug treatments are widely available. Effective interventions are required to remedy this incongruity
in current practice.
Methods: This study reviewed randomised controlled trials (RCT) involving fully qualified healthcare professionals
caring for patients with a fragility fracture in all healthcare settings. Any intervention designed to modify the
behaviour of healthcare professionals or implement a service delivery change was considered. The main outcomes
were BMD scanning and osteoporosis treatment with anti-resorptive therapy. The electronic databases Medline and
Embase were searched from 1994 to June 2010 to identify relevant articles in English. Post-intervention risk
differences (RDs) were calculated for the main outcomes and any additional study primary outcomes; the trials
were meta-analysed.
Results: A total of 2814 potentially relevant articles were sifted; 18 were assessed in full text. Nine RCTs evaluating
ten interventions met the inclusion criteria for the review. All were from North America. Four studies focused on
patients with a hip fracture, three on fractures of the wrist/distal forearm, and two included several fracture sites
consistent with a fragility fracture. All studies reported positive effects of the intervention for the main study
outcomes of BMD scanning and osteoporosis treatment. For BMD scanning the overall risk ratio (95% CI) was 2.8
(2.16 to 3.64); the RD was 36% (21% to 50%). For treatment with anti-resorptive therapy the overall risk ratio (95%
CI) was 2.48 (1.92 to 3.2); the RD was 20% (10% to 30%).
Conclusions: All interventions produced positive effects on BMD scanning and osteoporosis treatment rates post-
fracture. Despite sizeable increases, investigation and treatment rates remain sub-optimal. Long-term compliance
with osteoporosis medications needs to be addressed, as the majority of studies reported treatment rates at six-
month follow up only. Studies would be more informative if treatment criteria were defined a priori to facilitate
understanding of whether patients were being treated appropriately and integrated economic analyses would be
helpful for informing policy implementation decisions.
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Osteoporosis is, ‘a progressive systemic skeletal disease
characterised by low bone mass and micro-architectural
deterioration of bone tissue, with a consequent increase
in bone fragility and susceptibility to fracture [1].’
Osteoporosis can be diagnosed clinically (vertebral frac-
ture in a 80 year old white female) or defined by a
T-score of -2.5 standard deviations or lower on bone
mineral density (BMD) scanning. It is well documented
that there is a large quality of care gap for patients with
this condition [2-11]. This has two main components:
firstly a failure to make a diagnosis of osteoporosis, and
secondly to manage the condition adequately once the
diagnosis has been made.
A fragility fracture is ‘a fracture caused by injury that
would be insufficient to fracture normal bone: the result
of reduced compressive and/or torsional strength of bone’
[12]. It is a strong indicator of underlying osteoporosis,
and it has been shown that adults who sustain a fracture
are over 50% more likely to have another at a different
anatomical site [13,14]. Therefore, a first fracture offers an
ideal opportunity to initiate investigation and, if indicated,
treatment for osteoporosis. However, studies of post-
fracture populations document screening and treatment
rates below 20% in most settings [5,8-11,15-20]. This is
despite the fact that BMD scans are effective at identifying
patients at high risk of fracture [21-23], and drug treat-
ments have been shown to significantly reduce the rates of
subsequent fragility fractures, even in individuals with
advanced bone loss and prevalent fractures [24-30].
Although published evidence-based guidelines exist for
the investigation and management of osteoporosis
[31-35], the gap between accepted recommendations for
osteoporosis care and current practice remains wide.
The reasons for this are unclear, although several bar-
riers have been suggested and explored [36-43].
Reported reasons include: lack of consensus as to who is
responsible for initiating treatment; lack of awareness by
patients and physicians of the treatment guidelines and
efficacy of medications for osteoporosis following fragi-
lity fracture; and the adverse effects and high costs of
medications. Recent studies have shown that 70% to
90% of PCPs wish to be more informed about the man-
agement of osteoporosis [39,41,42], and with PCPs
assuming the prime responsibility for addressing osteo-
porosis over recent years, this is an ideal setting in
which to implement change.
The aim of this review is to assess within randomised
controlled trials (RCTs) the effectiveness of interven-
tions to improve the investigation (BMD scanning) and
management of osteoporosis (treatment with anti-
resorptive therapy) in patients following a fragility
fracture.
Methods
Criteria for considering studies for this review
Types of studies
This review focused on RCTs as they provide the least
biased estimate of the effectiveness of an intervention.
Types of participants and settings
This review focused on fully qualified healthcare profes-
sionals of any discipline caring for patients with a fragi-
lity fracture. All healthcare settings were included, i.e.,
community, primary, secondary, and tertiary care.
Types of interventions
This review focused on any intervention or combination
of interventions designed to improve the investigation
and management of osteoporosis following fragility frac-
ture by modifying the behaviour of healthcare profes-
sionals or implementing a service delivery change, with
usual care as comparator.
Outcome measures
The main review outcomes of interest were BMD scan-
ning and osteoporosis treatment with anti-resorptive
therapy. Other outcomes considered were: diagnosis of
osteoporosis, prescribing of calcium and vitamin D, and
economic variables. A study was required to report on
at least one of the main review outcomes to be consid-
ered for this review.
Search methods for identification of studies
The electronic databases Medline and Embase were
searched from 1994 (reflecting the introduction of BMD
scanning and use of anti-resorptive medications such as
the bisphosphonates into practice) to June 2010. The
search strategy incorporated the Cochrane RCT sensitiv-
ity maximising filter combined with selected MeSH
terms and free text terms related to interventions to
improve investigation and management of osteoporosis
following fragility fracture (see Additional File 1 for the
search strategy used in full). The search was limited to
English language articles.
In addition to the electronic searches, the reference
lists of relevant studies were hand searched to identify
any further relevant studies, and the following were con-
tacted to enquire about any additional published or
unpublished data relevant to this review: National
Osteoporosis Society (UK), National Osteoporosis Foun-
dation (US), International Osteoporosis Foundation, and
experts in the field.
Data collection and analysis
Selection of studies
One review author (EAL) screened all titles and
abstracts of retrieved studies in Endnote. If a study met
the initial selection criteria or its eligibility could not be
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retrieved. Both review authors then independently
assessed the full text for inclusion status, and any dis-
agreements were resolved through discussion.
Data extraction and management
EAL undertook data abstraction of each of the included
studies using a modified Cochrane Effective Practice and
Organisation of Care (EPOC) Data Collection Checklist.
The data extraction form was pilot tested on one
included study. Data was extracted on study design,
study objectives, participants, instrument reliability and
validity, type of interventions, sample size, statistical
power, primary and secondary study findings, statistical
tests used, and associated statistical and clinical signifi-
cance. MPE independently assessed the data extracted
and conclusions drawn.
Assessment of risk of bias in included studies
We used The Cochrane Collaboration’s tool for asses-
sing risk of bias on six standard criteria: adequate
sequence generation, concealment of allocation, blinded
or objective assessment of primary outcome(s), ade-
quately addressed incomplete outcome data, free from
selective reporting, and free of other risk of bias [44].
We used three additional criteria specified by the EPOC
Review Group: similar baseline characteristics, similar
baseline outcome measures, and adequate protection
against contamination [45].N os t u d i e sw e r ee x c l u d e d
because of poor methodological quality.
Measures of treatment effect
We report the main results for each study in natural
units extracted from the results presented in articles.
Only the main review outcomes, as well as additional
study primary outcomes are reported in full. We had
planned to report adjusted risk differences for the
review outcomes that adjust for baseline compliance.
However, clinicians were unlikely to test those who have
been tested or treat those who were already treated for
osteoporosis, making the notion of baseline compliance
with the review outcomes less meaningful. Therefore,
post-intervention risk differences (RD) were calculated
and reported instead. For a study to be included in the
review, it had to report actual numbers of patients
receiving a BMD scan or anti-resorptive treatment for
osteoporosis following fragility fracture to enable the
post-intervention RD to be calculated (one study was
rejected on these grounds). As an overall summary mea-
sure of effectiveness, the risk ratio and RDs were calcu-
lated using meta-analysis for both of the main outcomes
of the review.
Results
Selection of studies for inclusion
Figure 1 describes the process from searching to study
inclusion. Searches of the electronic databases to June
2010 yielded a total of 2,814 potentially relevant articles
(following de-duplication). Following review of titles and
abstracts, we obtained 18 articles for assessment in full
text. Nine RCTs met the inclusion criteria for the review
[46-54], with nine being excluded for the reasons
detailed in Figure 1 [55-63]. No additional potential stu-
dies were identified through hand-searching reference
lists of articles, or by contacting experts in the field or
osteoporosis foundations/societies.
Characteristics of study design and setting
Table 1 describes the included studies. There were eight
two-arm RCTs [46,48-54] and one three-arm RCT [47].
Five of the studies were conducted in the US
[46,47,50,53,54] and four in Canada [48,49,51,52]. Four
of the studies were set in tertiary care university hospi-
tals or medical centres [46,48,53,54], with the interven-
tion being targeted at primary care physicians (PCPs) in
three of them [46,48,54]. Two studies were set solely in
p r i m a r yc a r e[ 4 7 , 5 0 ] .T h er e m aining three studies were
set in hospital [49,51,52] with the PCP being the target
of the intervention in two of them [51,52]. The unit of
allocation was the patient in seven [46-49,52-54], the
physician in one [50], and the family practice in one
[51]. It was not possible to produce an overall number
of sites and healthcare professionals; the studies
included 3,302 patients.
Four studies focused on patients with a hip fracture
[46,48,49,53], three on fractures of the wrist/distal fore-
arm [51,52,54], and two included several fracture sites
consistent with a fragility fracture [47,50]. One study
specified that the fracture was a fragility fracture [54],
and four that the fracture was low energy/minimal
trauma [46,48,51,53], but the remaining four studies did
not discriminate by mechanism of injury [47,49,50,52].
Types of intervention
The intervention (content and method of delivery) and
the care delivered to the control groups are described in
Table 1. Two of the interventions were directed at the
PCP through patient education [46,48], one was an elec-
tronic medical record (EMR) reminder sent to the PCP
[47], one included an EMR reminder to the PCP plus a
patient reminder [47], three incorporated both PCP and
patient education [50-52], and three were service deliv-
ery changes [49,53,54]. Two of the service delivery
changes took the responsibility of investigating and
treating the osteoporosis out of the hands of the PCP
[49,53], and in one the investigation was carried out but
the results were sent to the PCP to act on [54].
Development of the intervention
With regards to the development of the intervention, only
two studies reported consulting with the professional
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for the intervention [46,47,49-52]. Consumer involvement
was not reported by any of the studies. In four of the stu-
dies, the authors report specific barriers to change that the
intervention was tailored to address [46,49,51,53].
Risk of bias in included studies
The risk of bias in included studies is reported in Table
2. Six trials reported adequate sequence generation, four
reported adequate concealment of allocation, and four
reported either adequately blinded or objective assess-
ment of primary outcome. All studies adequately
addressed incomplete outcome data, but only for two
studies did it appear that they were free from selective
reporting. Seven studies were judged to be free from
other biases; one of the other two studies was stopped
early, reporting that it was deemed unethical to continue
following an interim analysis. It is unclear if this interim
analysis was pre-specified. Eight studies had similar
baseline characteristics and all had similar baseline out-
come measures (for treatment but not for BMD scan-
ning). Three studies were judged to have adequate
protection against contamination.
Although producing summary scores or categories
across the various risk of bias criteria is not
recommended, the results in Table 2 suggest that only
o n e - t h i r do ft h es t u d i e sw e r el i k e l yt ob ea tl o wr i s ko f
bias.
Effects of interventions
Review outcomes and study primary outcomes of
included studies are reported in Table 3. With regards
to the main review outcomes of BMD scanning and
osteoporosis treatment with anti-resorptive therapy, all
studies report positive effects of the interventions. The
results are shown in Forest Plots in Figures 2 to 5. For
BMD scanning the overall risk ratio (95% CI) was 2.8
(2.16 to 3.64) and there was a small to medium, non-
significant amount of heterogeneity (I
2 42%); the RD
was 36% (21% to 50%). For treatment with anti-resorp-
tive therapy the overall risk ratio (95% CI) was 2.48
(1.92 to 3.2) and there was no heterogeneity (I
2 7%); the
RD was 20% (10% to 30%). Funnel plots (Additional File
2) suggest some asymmetry, but there are too few stu-
dies to formally assess this.
Other outcomes
Calcium and vitamin D use was reported in four studies
[48,51,52,54], but there was only a statistically significant
difference between control and intervention group in
Figure 1 Study Flowchart.
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Reference Setting Design Trial
subjects
Inclusions Exclusions Content and method of
delivery of intervention
Control group Comments
Gardner
2005 [46]
One tertiary care
university medical
centre; primary
care; New York,
USA.
Two arm
RCT; patient
randomised.
No power
calculation
reported.
F/U period:
six months.
Clinicians
PCPs*
(further
details not
reported).
Patients
N = 80.
Mean age: 82
years.
78% female.
Low energy hip fracture. Antiresorptive medication
use, under 65 years,
alcoholism, dementia.
Content
15 mins patient
education; five questions
to take to PCP regarding
investigation, diagnosis
and management of
osteoporosis; patient
reminder at six weeks
post-op.
Delivery
Visit by clinical research
coordinator during
hospitalization; printed
copy of questions; phone
call.
Prior to discharge,
patients given two page
pamphlet on fall
prevention based on a
National Osteoporosis
Foundation publication.
Feldstein
2006 [47]
One Pacific
Northwest non-
profit health
maintenance
organization
(HMO) involving
15 primary clinics;
USA.
Three arm
RCT; patient
randomised.
Power
calculation
reported
and
sufficient
numbers
recruited.
F/U period:
six months.
Clinicians
159 PCPs.
Patients
N = 327.
Age range =
50-89 years.
100% female.
Individuals aged 50 to 89
who had been HMO
members for at least 12
months and sustained a
study defined fracture
(any clinical fracture
except skull, facial, finger,
toe, ankle or any open
fracture).
Previous BMD scan/
osteoporosis treatment,
malignancy, chronic renal
failure, organ transplant,
cirrhosis, dementia, men,
nursing home residents,
no address, no primary
care provider, research
centre employees.
Intervention one:
Content
Physician alert and
education.
Delivery
Patient-specific electronic
medical record (EMR) in-
basket message from
chairman of the
osteoporosis quality-
improvement committee;
internal and external
guideline resources;
second message sent at
three months if no
investigation/treatment
carried out.
Intervention two:
Content
Physician alert and
education; patient
reminder and education
copied to PCP.
Delivery
Patient-specific EMR in-
basket message as above
with copy of patient
reminder; printed
educational materials in
advisory letter to patient.
Usual care - if patient is
hospitalized for a fracture,
the PCP receives a copy
of the discharge
summary and the patient
is followed-up by
orthopaedists in a
fracture clinic.
Except for exclusion of
open fractures, no
attempt made to
distinguish between
fractures that resulted
from high force as data
not reliably available
electronically.
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Davis 2007
[48]
One tertiary care
university hospital;
primary care;
Vancouver,
Canada.
Two arm
RCT; patient
randomised.
Power
calculation
reported.
F/U period:
six months.
Clinicians
PCPs (further
details not
reported).
Patients
N = 48.
Mean age:
82.6 years
(control), 80.4
years.
(intervention)
71% female.
All women and men ≥
60 years residing in
Vancouver admitted with
a minimal trauma hip
fracture.
On osteoporosis
treatment, dementia/
cognitive impairment,
unable to communicate
in English, severe medical
pathology (e.g. cancer,
chronic renal failure).
Content
Patient education and
advice to visit PCP for
further investigation;
physician alert.
Delivery
Osteoporosis information;
letter for patient to take
to PCP from orthopaedic
surgeon.
Usual care for the
fracture and a phone call
at three months (general
health inquiry) and 6
months to determine
whether osteoporosis
investigation and
treatment had occurred.
Minimal trauma defined
as falling from a
standing height or less.
Power calculation
required sample size of
44. 48 subjects recruited
but 20 in control group
and 28 in intervention
group. No explanation
for uneven numbers
between groups
reported.
Majumdar
2007 [49]
Three hospitals in
Capital Health
System;
Edmonton,
Alberta, Canada.
Two arm
RCT; patient
randomised.
Power
calculation
reported
and
sufficient
numbers
recruited.
F/U period:
six months.
Clinicians
One case-
manager
(registered
nurse), one
study
physician.
Patients
N = 220.
Median age:
74 years.
60% female.
Community-dwelling
patients ≥ 50 years with
hip fracture undergoing
surgical fixation with no
contraindications to
bisphosphonates and
able to provide (or have
a proxy provide)
informed consent.
Delirium, dementia, on
osteoporosis treatment,
pathologic fractures,
patients in nursing
homes or long-term care
facilities.
Content
Usual care; patient
education; outpatient
BMD test; prescription for
bisphosphonates for
patients with low bone
mass; communication to
PCPs regarding results
and treatment plans.
Delivery
Case-manager - provided
one-on-one counselling;
arranged BMD test;
obtained prescription
from study physician to
be dispensed by local
community pharmacy.
Study personnel provided
counselling about fall
prevention and intake of
calcium and vitamin D;
educational materials
from osteoporosis
Canada provided and
patients asked to discuss
the material with their
PCP.
Canadian guidelines
recommended
pharmacologic
osteoporosis therapy in
patients with a fragility
fracture after age 50
years or menopause
and a BMD T score ≤
-1.5.
Patients in control
group received more
education and study-
related attention than
true usual care as
practiced in most
Canadian or US centres.
Solomon
2007 [50]
Primary care
(patients all
beneficiaries of
HBCBSNJ
Δ health
care insurer); New
Jersey, USA.
Two arm
cluster RCT;
physician
randomised
(provided at
least four
patients per
physician).
Analysis
adjusted for
clustering.
No power
calculation
reported. F/
U period: 10
months.
Clinicians
434 PCPs.
Mean age: 50
years. 17%
female.
Patients
N = 1973
(229 with
fractures).
Mean age: 69
years
(control), 68
years
(intervention).
92% female.
HBCBSNJ beneficiaries
who had at least two
years of enrolment and a
prescription drug benefit;
required to have filed at
least one prescription
claim in each of the two
baseline years; age ≥ 45
years; prior fracture of
hip, spine, forearm or
humerus.
Previous BMD scan or
prescription for
osteoporosis medication
during baseline 26
months; patients whose
PCP had < four eligible
patients at risk for
osteoporosis.
Content
Physician education;
physician alert; patient
education; patient
invitation to attend BMD
scan.
Delivery
One-on-one educational
visit with PCP conducted
by specially trained
pharmacists who work
with HBCBSNJ as
physician educators;
continuing medical
education (CME)
program; list of at-risk
patients given to PCP
and discussed at
meeting; printed
educational materials and
letter from HBCBSNJ to
patient; automated
phone call invitation for
BMD scan.
No description, assumed
usual care.
Figures for subgroup of
patients with prior
fracture included in
review taken from
baseline characteristics
of wider study
population.
The study paid for
doctors to apply for
CME credit if they
completed a post-visit
test.
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7Table 1 Characteristics of included studies (Continued)
Cranney
2008 [51]
Emergency
departments or
fracture clinics of
five hospitals (two
of which were
teaching
hospitals); 119
primary care
practices; Ontario,
Canada.
Two arm
cluster RCT;
family
practice
randomised.
Analysis
adjusted for
clustering.
Power
calculation
reported
and
sufficient
numbers
recruited.
F/U period:
six months.
Clinicians
174 PCPs.
55% female.
54 practiced
in rural
settings.
Patients
N = 270.
Mean age:
69.8 years
(control), 68.1
years
(intervention).
100% female.
Family practices in
Kingston, Ontario and the
surrounding southeastern
Ontario region drawn
from the Canadian
Medical Association
directory; post-
menopausal women who
had sustained a wrist
fracture (confirmed by x-
ray).
Osteoporosis medication
use, traumatic wrist
fracture, unable to
communicate in English
or unable to give
consent.
Content
Physician alert; physician
education; patient
reminder recommending
F/U visit with PCP;
patient education.
Delivery
Personalised letter mailed
to PCP by research
coordinator at two weeks
and two months post-
fracture; two page
educational tool and
treatment algorithm from
Osteoporosis Canada’s
clinical practice
guidelines; mailed
patient reminder letter at
two weeks and two
months post-fracture;
educational booklet.
Usual care. Patients and
PCPs were not sent any
communication until trial
completed.
Majumdar
2008 [52]
Two emergency
departments and
two fracture
clinics, Capital
Health; primary
care; Edmonton,
Alberta, Canada.
Two arm
RCT; patient
randomised.
Power
calculation
reported
and
sufficient
numbers
recruited.
F/U period:
six months.
Clinicians
266 PCPs.
Patients
N = 272.
Median age:
60 years.
77% female.
Age ≥ 50 years and any
distal forearm fracture,
regardless of cause.
Bisphosphonate use,
unable or unwilling to
provide informed
consent, no fixed address,
residing outside Capital
Health region, residing in
a long-term care facility.
Content
Patient education and
advice to discuss
osteoporosis with PCP;
patient-specific reminders
to PCPs; physician
education.
Delivery
Phone counselling
session to patients by
experienced registered
nurse; physician reminder
sent by fax or mail;
evidence based
treatment guidelines
endorsed by opinion
leaders sent to PCPs.
Given Osteoporosis
Canada pamphlet and
encouraged to discuss
with PCP, second copy
mailed to patient. PCPs
routinely notified that
their patients had been
treated for a wrist
fracture and informed of
F/U plans and
appointment.
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Miki 2008
[53]
One tertiary care
university medical
centre, inpatient
and outpatient
clinic; Connecticut,
USA.
Two arm
RCT; patient
randomised.
Power
calculation
reported.
F/U period:
six months
Clinicians
One male
orthopaedic
surgeon.
Patients
N = 62.
Mean age:
79.2 years.
71% female.
All English-speaking
patients admitted with
low-energy hip fracture.
Osteoporosis medication
use, pathologic fracture.
Content
Patient education;
osteoporosis evaluation;
calcium and vitamin D
commenced; patient
review and
bisphosphonate
commenced as
appropriate; monitoring
of adherence to
medication and
complications; transfer of
responsibility for
medication adherence
and patient management
to PCP after six months.
Delivery
15 mins education to
patient and families
whilst in hospital from
one of the investigators;
inpatient blood tests and
BMD scan; F/U
outpatient orthopaedic
clinic appointment
between two weeks and
one month post-op;
phone call to patient or
clinic visit at two and six
months.
15 mins education on hip
fractures, fracture
prevention and
osteoporosis from one of
the investigators; advised
to see PCP for
osteoporosis evaluation;
commenced on calcium
and vitamin D.
Trial stopped following
interim analysis before
pre-defined sample size
reached due to ethical
reasons.
Rozental
2008 [54]
One university
tertiary care
centre,
orthopaedic
outpatient clinic;
primary care;
Boston, USA.
Two arm
RCT; patient
randomised.
Power
calculation
reported
and
sufficient
numbers
recruited.
F/U period:
six months.
Clinicians
PCPs,
orthopaedic
surgeons
(further
details not
reported).
Patients
N = 50.
Mean age: 65
years.
92% female
Women > 50 years or
men > 65 years; fragility
fracture of distal part of
radius.
High energy trauma,
BMD scan within two
years of fracture, current
HRT or antiresorptive
medication use.
Intervention one:
Content
BMD scan with results
forwarded to PCP.
Delivery
Scan ordered by
orthopaedic surgeon
during patient’s initial
office visit for fracture
care; results forwarded
by mail and email to
PCP.
Intervention two:
Letter sent by email and
mail to PCP outlining
national guidelines for
evaluating and treating
osteoporosis after fragility
fracture; the guidelines
included ordering a BMD
scan within six months of
injury.
Intervention two
considered to be close
enough to usual care to
use as a control group.
Fragility fracture defined
as those resulting from
a standing height or
less.
*PCPs = Primary care physicians.
ΔHBCBSNJ = Horizon Blue Cross Blue Shield of New Jersey.
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Reference Adequate
sequence
generation
Concealment
of allocation
Blinded or
objective
assessment of
primary
outcome(s)
Adequately
addressed
incomplete
outcome
data
Free from
selective
reporting
Free from other risk of bias Similar
baseline
characteristics
Similar
baseline
outcome
measures
Adequate protection against
contamination
Gardner
2005 [46]
Yes Unclear Unclear Yes Unclear - protocol
not published; trial
registration
number not
reported.
Unclear - only approx. 20% of
patients approached were included
in the study. 40% of patients
deemed eligible declined to enter
study.
Unclear - not
reported.
Yes for
treatment;
unclear for
BMD
scanning.
Unclear - patient randomised,
PCPs not reported.
Feldstein
2006 [47]
Yes Yes Yes Yes Unclear - protocol
not published; trial
registration
number not
reported.
Yes Yes Yes Unclear - patient randomised:
15 primary care clinics involved
with 159 PCPs, average one to
three patients per PCP.
Davis 2007
[48]
Yes No No Yes Unclear - protocol
not published; trial
registration
number not
reported.
Yes Yes Yes for
treatment;
unclear for
BMD
scanning.
Unclear - patient randomised,
PCPs not reported.
Majumdar
2007 [49]
Yes Yes Yes Yes Yes for primary
outcome; no for
secondary
outcomes.
Yes Yes Yes for
treatment;
unclear for
BMD
scanning.
Unclear - possibility of
contamination if control and
intervention patients on ward
at same time.
Solomon
2007 [50]
Unclear Unclear Unclear Yes Unclear - protocol
not published; trial
registration
number not
reported.
Yes Yes Yes Unclear - physician
randomised but practices in
which they worked not
reported on.
Cranney
2008 [51]
Yes Yes Yes Yes Unclear - protocol
not published; trial
registration
number not
reported.
Yes Yes Yes Yes
Majumdar
2008 [52]
Yes Yes Yes Yes Yes Yes Yes Yes for
treatment;
unclear for
BMD
scanning.
Yes
Miki 2008
[53]
Unclear Unclear No Yes Unclear - protocol
not published; trial
registration
number not
reported.
Unclear - stopped early as deemed
unethical to continue following
interim analysis.
Yes Yes Yes
Rozental
2008 [54]
Unclear Unclear Unclear Yes Unclear - protocol
not published; trial
registration
number not
reported.
Yes Yes Yes for
treatment;
unclear for
BMD
scanning.
Unclear - patient randomised,
PCPs not reported.
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7Table 3 Reported study outcomes
Reference Reported study outcomes Osteoporosis medication use Comments
Gardner
2005 [46]
Control Intervention Post-
intervention
RD
Δ
Drugs used
N (%) N (%) (%) Bisphosphonates.
BMD scan 6/36 (17) 12/36 (33) 17 Data source for drug utilisation
Osteoporosis
treatment
6/36 (17) 10/36 (28) 11 Patient self-report.
Feldstein
2006 [47]
Control Intervention Post-
intervention
RD
Drugs used Secondary outcomes included regular physical activity, total caloric expenditure,
total calcium intake and patient satisfaction.
N (%) N (%) (%) Bisphosphonate, calcitonin, selective
estrogen receptor modulator,
estrogen medication.
EMR Data source for drug utilisation
BMD scan 2/101 (2) 40/101 (40)* 38 Electronically from outpatient
pharmacy system.
Osteoporosis
treatment
5/101 (5) 28/101 (28)* 23 No significant differences between the EMR and the EMR + patient reminder arm
with respect to BMD scanning and osteoporosis treatment.
EMR +
patient
reminder
BMD scan 2/101 (2) 36/109 (33)* 31
Osteoporosis
treatment
5/101 (5) 22/109 (20)* 15
Davis 2007
[48]
Control Intervention Post-
intervention
RD
Drugs used 4/20 (20%) of the control group and 11/28 (39%) of the intervention group
received a diagnosis of osteoporosis but this difference was not significant.
N (%) N (%) (%) Bisphosphonates.
BMD scan 0/20 (0) 8/28 (29)* 29 Data source for drug utilisation
Osteoporosis
treatment
0/20 (0) 15/28 (54)* 54 Patient self-report.
Calcium +
vitamin D
6/20 (30) 11/28 (39) 9
Exercise
prescription
0/20 (0) 9/28 (32)* 32
Majumdar
2007 [49]
Control Intervention Post-
intervention
RD
Drugs used Secondary outcomes included “appropriate care” (BMD testing with treatment if
bone mass low), recurrent fractures, admissions to hospital and death.
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7Table 3 Reported study outcomes (Continued)
N (%) N (%) (%) Bisphosphonates - alendronate or
risedronate.
Of 120 who underwent BMD testing, 25 (21%) did not have low bone mass. Of the
95 patients with low bone mass, 41 (43%) had a T score at hip or spine between
-1.5 and -2.5, and 54 (57%) had a T score of ≤ -2.5.
BMD scan 32/110 (29) 88/110 (80)* 51 Data source for drug utilisation
Osteoporosis
treatment
24/110 (22) 56/110 (51)* 29 Not reported.
Solomon
2007 [50]
Control Intervention Post-
intervention
RD
Drugs used Only results adjusted for baseline characteristics significant, unadjusted results
insignificant.
N (%) N (%) (%) HRT, calcitonin, raloxifene,
bisphosphonates, teriparatide.
BMD scan 4/95 (4) 11/134 (8)* 4 Data source for drug utilisation
Osteoporosis
treatment
1/95 (1) 6/134 (4) 3 Health-care utilisation data.
Cranney
2008 [51]
Control Intervention Post-
intervention
RD
Drugs used 38/141 (27%) of control patients and 43/120 (36%)of intervention patients received
calcium or vitamin D. This difference was not statistically significant.
N (%) N (%) (%) One patient raloxifene, 49
bisphosphonates.
Results for osteoporosis treatment reported for all patients randomised (270)
whereas BMD scanning and calcium or vitamin D only reported for those
completing follow up (261).
BMD scan 36/141 (26) 64/120 (53)* 28 Data source for drug utilisation Secondary outcomes included discussion with PCP regarding osteoporosis and
changes in the participant’s knowledge of osteoporosis.
Osteoporosis
treatment
15/145 (10) 35/125 (28)* 18 Patient self-report. Although baseline BMD scanning was reported, the ARD cannot be calculated as
the numbers at baseline were different to those included in the analysis.
Majumdar
2008 [52]
Control Intervention Post-
intervention
RD
Drugs used 58/135 (43%) of control patients and 91/137 (66%) of intervention patients
received calcium and vitamin D. This difference was statistically significant.
N (%) N (%) (%) Bisphosphonates. Results adjusted for acid peptic disease, osteoarthritis, current smoking, calcium
and vitamin D use as significant differences found between intervention and
control groups for these 5 variables.
BMD scan 24/135 (18) 71/137 (52)* 34 Data source for drug utilisation Secondary outcomes included “appropriate care” and quality of life.
Osteoporosis
treatment
10/135 (7) 30/137 (22)* 14 Patient self-report confirmed
through dispensing records of local
pharmacies.
Of the 95 patients who underwent BMD testing, 27 (28%) had normal bone mass,
49 (52%) had osteopenia (T score -1.0 to - 2.5), and 19 (20%) had osteoporosis (T
score ≤ -2.5) at either the hip or spine.
Miki 2008
[53]
Control Intervention Post-
intervention
RD
Drugs used No p-value given for difference in BMD scanning between groups.
N (%) N (%) (%) One patient calcitonin nasal spray,
21 bisphosphonates.
For those starting osteoporosis treatment the post-intervention RD was 44% but
one patient in the control group and five in the intervention group stopped
before six months.
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7Table 3 Reported study outcomes (Continued)
BMD scan 7/24 (29) 26/26 (100) 71 Data source for drug utilisation In the intervention group, 38% of those receiving treatment for osteoporosis had
at least one T score of less than -2.5.
Osteoporosis
treatment
7/24 (29) 15/26 (58)* 29 Patient self-report. Although baseline BMD scanning was reported, the ARD cannot be calculated as
the numbers at baseline were different to those included in the analysis.
Secondary outcomes included new fracture during the six month follow up period.
Rozental
2008 [54]
Control
(Intervention
two)
Intervention
One
Post-
intervention
RD
Drugs used Intervention two sufficiently close to usual care as to be considered as the control
group.
N (%) N (%) (%) One teriparatide, one calcitonin, 11
bisphosphonates.
BMD scan 7/23 (30) 25/27 (93)* 62 Data source for drug utilisation 4/23 (17%) of control patients and 15/27 (56%) of intervention patients received
calcium and vitamin D. This difference was not statistically significant.
Osteoporosis
treatment
5/23 (22) 8/27 (30) 8 Patient self-report and review of
medical records.
Calcium and vitamin D counted as osteoporosis treatment in original paper so
post-intervention RD reported here substantially less (8% c.f. 48%). There was a
significant difference between groups when calcium and vitamin D were included
as osteoporosis treatment but no p-values reported with these excluded.
Treatment
discussed
with PCP
8/23 (35) 24/27 (89)* 54 2/23 (9%) of patients in the control group and 9/27 (33%) of patients in the
intervention group received a diagnosis of osteoporosis.
*statistically significant difference between groups (p < 0.05).
ΔRD = risk difference.
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7one (43% versus 66%) [52]. Two studies reported rates
of osteoporosis diagnosis but did not specify what con-
stituted this diagnosis [48,54]. One study reported the
percentage of patients undergoing BMD scan given a
diagnosis of osteoporosis (T score ≤-2.5) [52]. None of
the studies reported concurrently economic outcomes,
but one trial group [49] subsequently published a sepa-
rate cost analysis of a case manager intervention that
suggested that the intervention was cost saving [63].
Two studies reported on ‘appropriate care’ [49,52].
Two studies reported primary outcomes other than
those addressed by this review [48,54]. One looked at
whether or not participants were prescribed exercise as
recommended by the 2002 Canadian Medical Associa-
tion Osteoporosis Clinical Practice Guidelines [48].
They found a statistically significant difference between
control and intervention groups with a post-intervention
RD of 32%. The other study looked at whether or not
osteoporosis had been discussed with the PCP and also
found a statistically significant difference between inter-
vention and control groups with a post-intervention RD
of 54% [54].
Discussion
We reviewed nine RCTs assessing the effectiveness of a
variety of interventions to improve the investigation and
management of osteoporosis following fragility fracture.
For both of the review main outcomes, BMD scanning
and osteoporosis treatment with anti-resorptive therapy,
all studies reported a positive effect of the intervention
with an overall 36% absolute increase in scanning rates
and a 20% absolute increase in treatment rates. Such
Figure 2 Risk ratio for bone mineral density scanning (Mantel-Haenszel, random effects).
Figure 3 Risk ratio for anti-resorptive drug treatment (Mantel-Haenszel, random effects).
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Page 13 of 17effects are clearly important. These results are broadly
in agreement with other recent reviews [64] though this
had a slightly different focus (patients at risk of osteo-
porosis) and so included different studies.
Whilst all studies reported positive effects, they have a
number of constraints that limit their informativeness.
All of the studies were conducted in North America.
This may limit their generalisability to other countries
and healthcare systems. Although we pooled the results
of the studies (reflecting their homogeneity of patient
groups and settings), there were still a range of types of
interventions and it is not possible to say that any one
intervention was more effective than any other. With
relatively low levels of control group performance, the
results suggest that any intervention is likely to be more
effective than usual care; it is not clear what would
happen in situations with higher rates of baseline perfor-
mance. In relation to this, it is relevant to point out that
this is a relatively recent body of literature with the old-
est trial reporting in 2005. In future it is likely that stu-
dies will be addressing improved levels of baseline
performance. In some studies it was not clear whether
or not treatment was appropriately linked to BMD scan-
ning result, with at least one study apparently reporting
treatment on BMD scan values that would not result in
treatment in the UK NHS [53]. Whilst it would be
expected that most patients should receive a BMD scan
post-fracture, the majority of studies failed to report
treatment criteria a priori making it difficult to interpret
treatment rates. One trial group reported an outcome of
guideline concordant ‘appropriate care’ [49,52]. This was
defined as a BMD test performed and osteoporosis
Figure 5 Risk difference for anti-resorptive drug treatment (Mantel-Haenszel, random effects).
Figure 4 Risk difference for bone mineral density scanning (Mantel-Haenszel, random effects).
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Page 14 of 17treatment provided to those with low bone mass; they
then defined low bone mass according to current guide-
lines. This maximises our understanding of the data by
considering those patients who were appropriately not
treated. In the 2007 study, the osteoporosis treatment
rate in the intervention group was 51%, yet the rate of
‘appropriate care’ was 67% [49]. Thus, 16% of patients
did not receive osteoporosis treatment following BMD
scan because they were not eligible for it. Nevertheless,
this study also highlights the fact that despite the overall
positive effects of the interventions, none of the studies
produced maximal rates of investigation and treatment.
In this particular study, 33% of patients did not receive
appropriate care.
All of the studies reported treatment rates at six
months follow-up, except for one that extended to 10
months [50]. Long-term compliance with osteoporosis
medications is not addressed and is something that will
need to be considered in future studies.
We assessed all studies for their risk of bias, and five of
the nine included studies had multiple unknown criteria
in Table 2 [46,48,50,53,54] It is unclear whether or not
these studies were actually at an increased risk of bias or if
this assessment was a consequence of poor reporting;
however, they tended to be smaller and to report more
uncertain results. It is not possible to exclude publication
bias. The funnel plots suggested the possible absence of
larger, less positive studies, but given the number of
included trials this can only be a subjective judgement.
The rationale for the interventions used was often
unclear. While four studies reported that the interven-
tion was tailored to identified barriers [46,49,51,53], the
other five did not. In addition, from some of the
descriptions given it was difficult to extract sufficient
detail to be confident that the interventions were being
described in a way that would make them replicable
[46-48,50,51,53]. It was also difficult to disentangle what
the investigators felt was the content of their interven-
tion (the active ingredients; e.g., persuasive communica-
tion) from the method that they chose to deliver it
(printed educational materials). Such distinction is
important in order to promote greater clarity in the
description of interventions. Recent reporting guidelines
have suggested that this will constrain scientific replica-
tion and limit the subsequent introduction of successful
interventions [65].
Investigators should be considering the economic
implications of their interventions and do not, on the
basis of this review appear to be doing so; no study con-
currently reported an integrated economic analysis of
the intervention. However, one trial group subsequently
reported an economic analysis of their case-manager
intervention that suggested the intervention was cost
saving [63].
The review had some limitations. Only articles pub-
lished in English were considered and only two electro-
nic databases were searched (Medline and Embase).
However, it is reassuring that examination outside of
the review of Web of Science, OVID Evidence Based
Reviews and Cochrane (to June 2010) by one of this
manuscript’s reviewers identified no additional eligible
studies (S. Majumdar, personal communication). Rather
than having full duplication of all activities, one author
(EAL) sifted the results of the search for included stu-
dies, although both authors assessed the eligibility of the
18 articles in which the full text was retrieved. One
author (EAL) abstracted data from the included studies;
this was checked by the second author.
Summary
All interventions demonstrated a positive effect on BMD
scanning and osteoporosis treatment post-fracture, regard-
less of healthcare setting, patient population, and type of
intervention. Despite this, only one of the studies reported
maximal investigation rates (all patients investigated) and
none reported maximal treatment rates. Follow-up did not
extend beyond 10 months in any of the studies; the issue
of long-term compliance with osteoporosis medications
will need to be addressed in future studies. To aid inter-
pretation of results, study authors should report treatment
criteria ap r i o r iand a measure of appropriate care.
Integrated economic analyses would be helpful when
considering widespread implementation.
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